Safety Study of PI-0824 to Treat Pemphigus Vulgaris

P

Peptimmune

Status and phase

Completed
Phase 1

Conditions

Pemphigus Vulgaris

Treatments

Drug: PI-0824

Study type

Interventional

Funder types

Industry

Identifiers

NCT00063752
PI-001

Details and patient eligibility

About

The purpose of this study is to determine if the use of PI-0824 in patients with Pemphigus vulgaris is safe.

Full description

Pemphigus vulgaris (PV) is an autoimmune disease affecting approximately 40,000 people worldwide. People with PV produce antibodies that attack the cells of the skin, resulting in blisters which, if left untreated, can lead to devastating infections and discomfort. Currently, most doctors who treat patients with PV will prescribe high-dose steroids and drugs that suppress the immune system in an effort to decrease the production of these antibodies. Unfortunately these medications are associated with serious and difficult side effects that often result in the discontinuation of their use. Peptimmune, Inc. has developed a new therapy for the treatment of PV, PI-0824. The goal of this therapy is to reduce the production of antibodies that cause PV blisters by acting only on the disease causing components of the immune system. It is hoped that use of PI-0824 will reduce or potentially eliminate the need for high dose steroids and drugs that suppress the immune system.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Currently experiencing a stable disease course and medication regimen. Currently taking daily corticosteroid therapy for PV.

Trial contacts and locations

8

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems